Literature DB >> 21997622

A methodological framework to enhance the clinical success of cancer immunotherapy.

Axel Hoos, Cedrik M Britten, Christoph Huber, Jill O'Donnell-Tormey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21997622     DOI： 10.1038/nbt.2000

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  16 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Authors:  Axel Hoos; Ramy Ibrahim; Alan Korman; Kald Abdallah; David Berman; Vafa Shahabi; Kevin Chin; Renzo Canetta; Rachel Humphrey
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 4.  A clinical development paradigm for cancer vaccines and related biologics.

Authors:  Axel Hoos; Giorgio Parmiani; Kristen Hege; Mario Sznol; Hans Loibner; Alexander Eggermont; Walter Urba; Brent Blumenstein; Natalie Sacks; Ulrich Keilholz; Geoffrey Nichol
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

Review 5.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

6.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 7.  Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

Authors:  Lothar H Finke; Kerry Wentworth; Brent Blumenstein; Natalie S Rudolph; Hyam Levitsky; Axel Hoos
Journal:  Vaccine       Date:  2007-09-27       Impact factor: 3.641

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

9.  Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Authors:  Cedrik Michael Britten; Sylvia Janetzki; Leah Ben-Porat; Timothy M Clay; Michael Kalos; Holden Maecker; Kunle Odunsi; Michael Pride; Lloyd Old; Axel Hoos; Pedro Romero
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

10.  Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).

Authors:  Sylvia Janetzki; Katherine S Panageas; Leah Ben-Porat; Jean Boyer; Cedrik M Britten; Timothy M Clay; Michael Kalos; Holden T Maecker; Pedro Romero; Jianda Yuan; W Martin Kast; Axel Hoos
Journal:  Cancer Immunol Immunother       Date:  2007-08-25       Impact factor: 6.968
View more
  26 in total

1.  Structured reporting of T cell assay results.

Authors:  Sylvia Janetzki; Axel Hoos; Cornelis J M Melief; Kunle Odunsi; Pedro Romero; Cedrik M Britten
Journal:  Cancer Immun       Date:  2013-07-15

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2018-06-27       Impact factor: 44.544

4.  Miniaturized and high-throughput assays for analysis of T-cell immunity specific for opportunistic pathogens and HIV.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Nadia Starc; Fabiola Landi; Franco Locatelli; Sergio Rutella; Gino Tripodi; Fabrizio Manca
Journal:  Clin Vaccine Immunol       Date:  2014-01-29

5.  Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.

Authors:  Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2016-03-11       Impact factor: 84.694

6.  Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Authors:  Valsamo Anagnostou; Mark Yarchoan; Aaron R Hansen; Hao Wang; Franco Verde; Elad Sharon; Deborah Collyar; Laura Q M Chow; Patrick M Forde
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

7.  Clinical evaluation of therapeutic cancer vaccines.

Authors:  Chizuru Ogi; Atsushi Aruga
Journal:  Hum Vaccin Immunother       Date:  2013-03-01       Impact factor: 3.452

Review 8.  Big opportunities for small molecules in immuno-oncology.

Authors:  Jerry L Adams; James Smothers; Roopa Srinivasan; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2015-07-31       Impact factor: 84.694

Review 9.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

10.  Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.

Authors:  Munjal Pandya; Kellee Britt; Brad Hoffman; Chen Ling; George V Aslanidi
Journal:  J Immunother       Date:  2015-09       Impact factor: 4.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.